The numbers don’t lie: The first biosimilar foray into the aflibercept category is going very well for Amgen. The intravitreal injectable market has been a complicated, highly contested arena for many years. The first-generation products are VEGF inhibitors, and a second-generation product that targets both the VEGF and Ang-2 pathways (faricimab, reference product Vabysmo). The … Continue reading Amgen’s Pavblu Makes Significant Inroads into the Aflibercept Market